| Expression pattern: |
UP |
| Associated gene: |
LDHA mRNA, LDHA |
| Associated microRNA: |
miR-889-3p |
| Biological function: |
circUBE2D2 acts as an oncogenic factor in HCC, promotes glycolysis and sorafenib resistance in vitro, and supports tumor growth in vivo. |
| Molecular mechanism: |
circUBE2D2 functions as a cytoplasmic miRNA sponge for miR-889-3p and regulates LDHA through the circUBE2D2/miR-889-3p/LDHA axis. |
| Biological pathway or process: |
glycolysis (promotes); drug resistance (promotes); ceRNA regulation (other); proliferation (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RT-qPCR; Actinomycin D / DRB Stability Assay; RNase R Treatment; Clinical Sample Validation; Survival Analysis; Transfection; CCK8; Luciferase Reporter Assay; Bioinformatics Analysis; Nuclear-Cytoplasmic Fractionation; Western Blot; In Vivo Animal Model |
| Clinical significance: |
Higher circUBE2D2 expression was associated with lower survival rate and unfavorable prognosis in HCC patients. |
| Description: |
circUBE2D2 is an up-regulated circRNA in HCC tissues and cells, and high expression is linked to poor patient survival. It promotes HCC glycolysis and sorafenib resistance by acting as a cytoplasmic sponge for miR-889-3p and regulating LDHA through the circUBE2D2/miR-889-3p/LDHA axis. Knockdown of circUBE2D2 suppresses xenograft tumor growth in vivo. |
| Confidence score: |
0.8222 |